Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib + Gemcitabine in Locally Advanced Pancreatic Cancer
NCT01395017Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jun 2011
- Primary completion
- Oct 2013
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 15
01
Overview
A Phase 2 trial of dasatinib in pancreatic cancer (PC), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Jun 2011; status: completed.
02
Drugs
dasatinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT01395017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01395017.